Novel Biologics for the Treatment of Pediatric Severe Asthma

被引：1

作者：

Licari, Amelia ^{[1
,2
]}

Castagnoli, Riccardo ^{[2
]}

Tondina, Enrico ^{[2
]}

Testa, Giorgia ^{[1
]}

Parisi, Giuseppe Fabio ^{[3
]}

Marseglia, Alessia ^{[2
]}

Brambilla, Ilaria ^{[1
,2
]}

Marseglia, Gian Luigi ^{[1
,2
]}

机构：

[1] Fdn IRCCS Policlin San Matteo, SC Pediat, Pavia, Italy

[2] Univ Pavia, Dept Pediat, Pavia, Italy

[3] Univ Catania, Dept Clin & Expt Med, Catania, Italy

来源：

CURRENT RESPIRATORY MEDICINE REVIEWS | 2019年 / 15卷 / 03期

关键词：

Benralizumab; children; dupilumab; mepolizumab; omalizumab; reslizumab; severe asthma; SEVERE EOSINOPHILIC ASTHMA; SEVERE ALLERGIC-ASTHMA; ANTI-IGE; IMMUNOGLOBULIN-E; DOUBLE-BLIND; AIRWAY INFLAMMATION; MONOCLONAL-ANTIBODY; QGE031; LIGELIZUMAB; RANDOMIZED-TRIAL; SERUM IGE;

D O I：

10.2174/1573398X15666190521111816

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

引用

页码：195 / 204

页数：10

共 50 条

[31] The potential of biologics for the treatment of asthma
Girolamo Pelaia
Alessandro Vatrella
Rosario Maselli
Nature Reviews Drug Discovery, 2012, 11 : 958 - 972
[32] Epidemiology of obstructive sleep apnea in patients with severe asthma under treatment with biologics
Cirri, Lorenzo
Rothe, Thomas
Latshang, Tsogyal Daniela
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[33] Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine
Mustafa, S. Shahzad
Patrawala, Sara
Khurana, Sandhya
CURRENT OPINION IN PULMONARY MEDICINE, 2022, 28 (03) : 266 - 273
[34] Do older patients with severe asthma respond to asthma biologics?
Soe, Wint Wah
Mittal, Rahul
Cook, Peter
Eames, Chellan
Kerley, Sumita
Whitfield, Ciara
Pantaleon, Ma
McCreery, Jodi
Freeman, Anna
Haitchi, Hans Michael
Kurukulaaratchy, Ramesh
Dennison, Paddy
Rupan, Hitasha
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[35] Exhaled nitric oxide as a clinical biomarker for choosing biologics for severe asthma treatment
Fuschillo, Salvatore
Heffler, Enrico
Maniscalco, Mauro
BIOMARKERS IN MEDICINE, 2020, 14 (07) : 499 - 502
[36] Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient
Rogers, Linda
Jesenak, Milos
Bjermer, Leif
Hanania, Nicola A.
Seys, Sven F.
Diamant, Zuzana
RESPIRATORY MEDICINE, 2023, 218
[37] Sputum eosinophilia is a useful biomarker for treatment failure of biologics for severe eosinophilic asthma
Smidt-Hansen, T.
Andersen, H. H.
Pedersen, L. M.
Bjerrum, A. S.
Skjold, T.
Poulsen, R.
Petersen, S. B.
Hoffmann, H. J.
Schmid, J.
EUROPEAN RESPIRATORY JOURNAL, 2022, 60
[38] Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma
Desai, Mauli
Haines, Adam
Oppenheimer, John J.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2024, 44 (04) : 737 - 750
[39] Criteria for Evaluating Response to Biologics in severe Asthma- the Biologics Asthma Response Score (BARS)
Milger-Kneidinger, K.
Korn, S.
Feder, C.
Fuge, J.
Muhle, A.
Schutte, W.
Skowasch, D.
Timmermann, H.
Suhling, H.
PNEUMOLOGIE, 2023, 77 : S108 - S108
[40] Unanswered questions on the use of biologics in pediatric asthma
Nieto, Antonio
El-Sayed, Zeinab A.
Gomez, Rene Maximiliano
Hossny, Elham
Wang, Jiu-Yao
Kalayci, Oemer
Morais-Almeida, Mario
Phipatanakul, Wanda
Pitrez, Paulo Marcio
Beltran, Cesar Fireth Pozo
Xepapadaki, Paraskevi
Papadopoulos, Nikolaos G.
WORLD ALLERGY ORGANIZATION JOURNAL, 2023, 16 (11):

← 1 2 3 4 5 →